Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07209722 · ClinicalTrials.gov registry record
PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 1,377
- Enrollment target
NCT07209722: Completed study, sponsored by University of Alabama at Birmingham.
NCT07209722 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 1,377 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07209722 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 1,377 participants
- Enrollment target
Study Summary
The purpose of the study is to learn more about health care providers' experiences and perspectives on prescribing HIV pre-exposure prophylaxis, also known as PrEP. Providers and patients in gynecology clinics were interviewed and completed surveys to measure the feasibility and preference of prescribing PrEP.
Primary Outcome
Number of participants receiving a new PrEP prescription during the recruitment period
Interventions
- BEHAVIORAL PrEP acronym (pre-exposure prophylaxis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,377 participants |
| Start Date | 2023-09-22 |
| Est. Completion | 2025-08-16 |
What the finished NCT07209722 record still lists
NCT07209722 is an observational study that tracks outcomes without assigning an intervention. Its 1,377 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which PrEP acronym (pre-exposure prophylaxis) is the first listed.
NCT07209722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07209722 about?
NCT07209722 is a clinical study titled "PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare". The purpose of the study is to learn more about health care providers' experiences and perspectives on prescribing HIV pre-exposure prophylaxis, also known as PrEP. Providers and patients in gynecology clinics were interviewed and completed surveys to measure the feasibility and preference of prescr...
What is the current status of trial NCT07209722?
This trial is currently completed. The enrollment target is 1,377 participants. The study started on 2023-09-22. Estimated completion is 2025-08-16.
What interventions are being tested in trial NCT07209722?
The interventions under investigation include: PrEP acronym (pre-exposure prophylaxis) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07209722?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI